



27 Birchwood
Avenue
London
N10 3BE

T +44 (0) 208 365 2185
m +44 (0) 7818012891
Info@phmrconsulting.com
www.phmrconsulting.com

Directors

Mark Ratcliffe
BSc MSc PhD

Peter Hudson
BSc Msc

Parkinsons Disease

Economic/ health outcome publication alerts added in
February 2008

Searches found 20 articles that met criteria: 6 are commercially significant of which 4 are business and scientific critical and are reviewed.

Papers reviewed this month:

Lewitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin PC, Sussman NM; 6002-US-005 Study Group Members of the 6002-US-005 Study Group. Adenosine A(2A) receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). *Ann Neurol.* 2008 Feb 27; [Epub ahead of print]

Linazasoro G; Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. *Clin Neuropharmacol.* 2008 Jan-Feb;31(1):19-24.

Liou HH, Wu CY, Chiu YH, Yen AM, Chen RC, Chen TF, Chen CC, Hwang YC, Wen YR, Chen TH. Natural history and effectiveness of early detection of Parkinson's disease: results from two community-based programmes in Taiwan (KCIS no. 11). *J Eval Clin Pract.* 2008 Feb 18; [Epub ahead of print]

phmr consulting ltd.
Registered in England
Number 6551482
Registered office
Melville House
8-12 Woodhouse
Road
London N12 0RG